Abstract Number: 1397 • 2019 ACR/ARP Annual Meeting
Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis
Background/Purpose: Clinical studies have demonstrated the efficacy of tocilizumab (TCZ) administered with methotrexate (MTX) in improving rheumatoid arthritis (RA) disease activity in patients who have…Abstract Number: 1435 • 2019 ACR/ARP Annual Meeting
Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis
Background/Purpose: Wnt signaling is an important regulator of bone remodeling and it is involved in the pathogenesis of focal and systemic bone loss in Rheumatoid…Abstract Number: 1887 • 2019 ACR/ARP Annual Meeting
Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis
Background/Purpose: Mitochondria are key regulators of metabolism, inflammation and cell death, with mitochondrial dysfunction being associated with several diseases. Though mainly found intracellularly, we recently…Abstract Number: 1999 • 2019 ACR/ARP Annual Meeting
NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion
Background/Purpose: Fibroblast-like synoviocytes (FLS) are key effector cells in the pathogenesis of rheumatoid arthritis (RA) through the increased cell migration, degradation of extracellular matrix, and…Abstract Number: 2154 • 2019 ACR/ARP Annual Meeting
Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis
Background/Purpose: In patients with rheumatoid arthritis(RA), elevated resting energy expenditure(REE) is associated with rheumatoid cachexia and protein catabolism driven by pro-inflammatory cytokines. IR is also…Abstract Number: 2292 • 2019 ACR/ARP Annual Meeting
Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?
Background/Purpose: During pregnancy, patients with rheumatoid arthritis (RA) can experience flares that might influence pregnancy outcomes. We aimed at assessing disease course during pregnancy and…Abstract Number: 2321 • 2019 ACR/ARP Annual Meeting
Subclinical Myocardial Dysfunction Assessed by Strain Imaging in Patients with Rheumatoid Arthritis and Spondyloarthritis
Background/Purpose: Although cardiovascular (CV) risk and mortality are increased in rheumatoid arthritis (RA) and spondyloarthritis (SpA), mechanisms resulting in CV risk excess and stratification are…Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…Abstract Number: 2365 • 2019 ACR/ARP Annual Meeting
Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus
Background/Purpose: Rheumatoid arthritis (RA) patients have a high prevalence of cardiovascular comorbidities including diabetes mellitus (DM). Past studies have suggested a potential beneficial effect of…Abstract Number: 2391 • 2019 ACR/ARP Annual Meeting
Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients
Background/Purpose: Tumor necrosis factor (TNF), a pathogenic inflammatory mediator in Rheumatoid Arthritis (RA), has been shown to play an essential role in the pathophysiology of insulin resistance.…Abstract Number: 2773 • 2019 ACR/ARP Annual Meeting
Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier
Background/Purpose: Tapering or stopping conventional and biologic DMARDs in patients with rheumatoid arthritis (RA) in stable remission may be feasible in a subset of patients…Abstract Number: 2874 • 2019 ACR/ARP Annual Meeting
Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Background/Purpose: Real-world evidence (RWE) is key to understanding post-approval long-term safety of medications. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA.…Abstract Number: 37 • 2019 ACR/ARP Annual Meeting
Intestinal Microbiota Dynamics in the Progression of Rheumatoid Arthritis
Background/Purpose: Intestinal microbial dysbiosis in patients with rheumatoid arthritis (RA) has raised the interest in studying the role of intestinal microbes in the pathogenesis of…Abstract Number: 118 • 2019 ACR/ARP Annual Meeting
Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity but This Interaction Is Altered in Rheumatoid Arthritis Patients
Background/Purpose: Regulatory T cells (Treg) are necessary for immune homeostasis but are functionally deficient in inflammatory/autoimmune diseases such as rheumatoid arthritis (RA). On the other…Abstract Number: 204 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Background/Purpose: RA patients have an increased risk of malignancy1 and deep-vein thrombosis and pulmonary embolism (DVT/PE)2 and high prevalence of anemia.3 The risks of anemia…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 56
- Next Page »